EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT

Alexander Rühle iD, Ranjan Subramani, Jie Su, Brian O'Sullivan, John N Waldron, Andrew Hope, Andrew Bayley, Andrew McPartlin, Nauman Malik, Scott V Bratman, Ali Hosni, John Kim und 9 weitere

The Laryngoscope · 2026

DOI: 10.1002/lary.70424 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Laryngoscope, 2026. Verfasst von Alexander Rühle und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Radiotherapy, Intensity-Modulated, Vocal Cord Dysfunction, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the prognostic importance of impaired vocal cord mobility (VCM) in T2N0 glottic cancer.

Methods

All patients with T2N0 glottic cancer treated with partial laryngeal IMRT in 2009–2021 in our institution were retrospectively reviewed. For comparison, cohorts with T1N0 and T3N0 disease were also included. Locoregional failure (LRF), disease‐free survival (DFS), and overall survival (OS) were compared among T1N0, T2N0 with normal VCM (T2‐Normal‐VCM), T2N0 with impaired VCM (T2‐Impaired‐VCM), and T3N0 groups. Multivariable analysis (MVA) assessed the prognostic value of VCM within the T2N0 group.

Results

A total of 642 cases were included: 288 T1N0, 224 T2N0 (147 T2‐Normal‐VCM, 77 T2‐Impaired‐VCM), and 130 T3N0. Median follow‐up was 5.0 years (IQR 3.4–6.2). Five‐year LRF for T1N0, T2‐Normal‐VCM, T2‐Impaired‐VCM, and T3N0 were 4% (95% CI 2–6), 9% (5–15), 27% (17–38), and 35% (27–44), respectively. Corresponding DFS was 83% (78–88), 80% (73–87), 55% (45–68), and 50% (41–60), while OS was 85% (80–90), 86% (80–92), 71% (61–83), and 59% (50–69), respectively. In T2N0, MVA confirmed that impaired VCM was associated with higher LRF (aHR 3.72 [95% CI 1.79–7.71], p < 0.001), lower DFS (aHR 2.74 [1.68–4.45], p < 0.001), and lower OS (aHR 2.07 [1.17–3.67], p = 0.013).

Conclusions

In this contemporary cohort, LRF rates increased stepwise from T1N0 to T2‐Normal‐VCM, T2‐Impaired‐VCM, and T3N0 glottic cancer. Within T2N0 disease, impaired VCM is an adverse prognostic factor, supporting subdivision into T2a (normal VCM) and T2b (impaired VCM) in future TNM revisions. Prospective studies are warranted to assess whether treatment intensification can improve outcomes for T2‐Impaired‐VCM disease. Level of Evidence 3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Laryngeal NeoplasmsRadiotherapy, Intensity-ModulatedVocal Cord DysfunctionNeoplasm Recurrence, LocalPrognosisVocal CordsNeoplasm StagingRetrospective StudiesDisease-Free SurvivalHumansMaleFemaleMiddle AgedAgedKaplan-Meier Estimate

Stichwörter der Autor:innen

TNM stagingglottic canceroutcomesradiotherapyvocal cord mobility

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Department of Biostatistics, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Department of Otolaryngology-Head & Neck Surgery, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Department of Otolaryngology-Head and Neck Surgery, Sinai Health System, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
  • Division of Medical Oncology, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

ORCID-Profile: Alexander Rühle

Zitieren

APA

Rühle, A., Subramani, R., Su, J., O'Sullivan, B., Waldron, J. N., Hope, A., Bayley, A., McPartlin, A., Malik, N., Bratman, S. V., Hosni, A., Kim, J., Witterick, I., de Almeida, J. R., Yao, C., Spreafico, A., Tsai, C. J., Tong, L., Xu, W., …, & Hahn, E. (2026). Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT. The Laryngoscope. https://doi.org/10.1002/lary.70424

Vancouver

Rühle A, Subramani R, Su J, O'Sullivan B, Waldron JN, Hope A, et al. Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT. The Laryngoscope. 2026. doi:10.1002/lary.70424

BibTeX
@article{Rhle2026,
  author = {Rühle, Alexander and Subramani, Ranjan and Su, Jie and O'Sullivan, Brian and Waldron, John N and Hope, Andrew and Bayley, Andrew and McPartlin, Andrew and Malik, Nauman and Bratman, Scott V and Hosni, Ali and Kim, John and Witterick, Ian and de Almeida, John R and Yao, Christopher and Spreafico, Anna and Tsai, C Jillian and Tong, Li and Xu, Wei and Huang, Shao Hui and Hahn, Ezra},
  title = {Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT},
  journal = {The Laryngoscope},
  year = {2026},
  doi = {10.1002/lary.70424}
}
Kostenlos starten →